Delivery Order SPE2DR25D2013-SPE2DR26F5QRF
- Not listed
- The Defense Logistics Agency has awarded a delivery order valued at $37,827.70 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. This competitively awarded, firm fixed price contract involves no set-aside designation and carries an ultimate completion date of November 18, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a leading...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $25,835.76 to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 mL) 3 mL vials, with an ultimate completion date of October 29, 2025. This competitive, firm fixed-price delivery order carries no set-aside designation and represents a direct purchase of pharmaceutical inventory to support federal medical supply needs. The place of performance is AmerisourceBergen's Corporate Office location in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $45,523.52 to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which carries a total value of $999,999,999.00 and extends through December 2026. The product will be delivered to...
- The Defense Logistics Agency has awarded AmerisourceBergen Drug Corp a delivery order valued at $14,560.32 for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL quantities. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of November 5, 2025, awarded on November 4, 2025. AmerisourceBergen will fulfill this order from its corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters operations. This delivery order...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $55,084.93 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) injectable medication. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of October 30, 2025, and performance to be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $3,759.96 to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials. This competitive award utilizes a firm fixed-price contract type with an ultimate completion date of September 10, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,837.41 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. This is a firm fixed-price contract with no set-aside designation, issued on July 10, 2025, with an ultimate completion date of July 11, 2025. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. This award represents a single delivery order under...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $12,917.25 for Ozempic 2 mg/dose (8 mg/3 mL) pharmaceutical supplies on October 31, 2025, with an ultimate completion date of November 3, 2025. This competitively awarded, non-set-aside contract represents a firm fixed price delivery order for diabetes medication to support federal medical procurement needs. The work is to be performed at AmerisourceBergen's Conshohocken, Pennsylvania location, which...
- The Defense Logistics Agency awarded a delivery order valued at $45,553.12 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 ml) injectable medication on December 4, 2025, with an ultimate completion date of December 5, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $9,595.25 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 ml) in 3 ml vials. This competitive, non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by December 9, 2025, with the award issued on December 8, 2025. AmerisourceBergen will fulfill this order from its corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- SPE2DR25D2013Indefinite Delivery Contract
- SPE2DR25D2013-SPE2DR26F5QRFDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $46,309.38 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. This competitive award, made on December 2, 2025, with an ultimate completion date of December 3, 2025, represents a firm fixed-price procurement of this diabetes medication for federal medical supply needs. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, the company's headquarters. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. As a prime pharmaceutical vendor, AmerisourceBergen supplies a comprehensive range of medications and medical supplies to support military healthcare systems and other federal customers, including the Defense Health Agency and U.S. Coast Guard. The company's substantial contract portfolio demonstrates its critical role in the federal medical supply chain, with this particular award reflecting ongoing demand for specialty diabetes medications within Department of Defense healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $46.3k | 12/1/25 |